Printer Friendly

CORTECH ISSUED TWO HUMAN NEUTROPHIL ELASTASE INHIBITOR PATENTS

 DENVER, June 23 /PRNewswire/ -- Cortech Inc. (NASDAQ: CRTQ) today announced the issuance of U.S. patents No. 5,214,191 and No. 5,216,022 covering two classes of the company's human neutrophil elastase inhibitors. A third related patent application has been allowed and is expected to issue as a patent shortly.
 One of the issued patents covers Cortech's lead elastase inhibitor, CE-1037. CE-1037 and all the compounds covered by its patent are licensed exclusively to Marion Merrell Dow Inc. (NYSE: MKC). Pursuant to its agreements with Marion Merrell Dow, Cortech is managing preclinical and clinical development of CE-1037 for adult respiratory distress syndrome (ARDS), cystic fibrosis and genetic emphysema. Compounds covered by the other issued patent represent candidates for evaluation and potential development directed toward dermal, ophthalmic and/or oropharyngeal indications.
 Cortech is a Denver-based biopharmaceutical company that is developing a variety of therapies for inflammatory diseases, allergies and selected autoimmune diseases. No product under development by Cortech has completed human clinical trials or demonstrated efficacy in treating human diseases. As yet, none of the company's elastase inhibitor compounds has been administered to humans. There can be no assurance that current research and development efforts will lead to marketable products.
 -0- 6/23/93
 /CONTACT: Kenneth R. Lynn of Cortech, 303-650-1200/
 (CRTQ MKC)


CO: Cortech Inc.; Marion Merrell Dow Inc. ST: Colorado IN: MTC SU:

MC -- DV001 -- 4910 06/23/93 10:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 23, 1993
Words:235
Previous Article:INDEPENDENT BANK CORPORATION DECLARES DIVIDEND
Next Article:MARION MERRELL DOW IN-LICENSES TWO DRUGS IN LATE-STAGE TRIALS FROM MERCK & CO.
Topics:


Related Articles
CORTECH ANNOUNCES INITIAL PUBLIC OFFERING
CORTECH RAISES $29.2 MILLION IN IPO
CORTECH AND MARION MERRELL DOW ADD CLINICAL INDICATIONS AND AMEND LICENSE AGREEMENT IN NEUTROPHIL ELASTASE INHIBITOR PROGRAM
CORTECH ELECTS NEW BOARD MEMBER
INCYTE AWARDED THIRD PATENT FOR BPI
CORTECH AND ONO COLLABORATE IN ORALELASTASE INHIBITOR DEVELOPMENT
Alexion Announces Issuance of Two U.S. Patents Covering a Class Of Novel Complement Inhibitors
Dyax Corp. Issued U.S. Patent Covering Novel Elastase Inhibitors
Corvas Announces Issuance of U.S. Patents on Serine Protease Inhibitors

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters